Based in New York City, Lexeo Therapeutics is a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Building on groundbreaking research from Weill Cornell Medicine and the University of California San Diego, Lexeo partners with preeminent institutions on the cutting edge of gene therapy research. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4 associated Alzheimer's disease programs, and is led by pioneers and experts with decades of collective experience in genetic medicines, rare disease drug development, manufacturing and commercialization.
For more information, please visit www.lexeotx.com.
Company Details
- Employees
- 82
- Founded
- -
- Address
- 345 Park Avenue South,
- Phone
- (212) 547-9879
- in****@****otx.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- lexeotx.com
- HQ
- New York, New York
Lexeo Therapeutics Questions
Lexeo Therapeutics's helpline number is (212) 547-9879
Lexeo Therapeutics's website is lexeotx.com
Lexeo Therapeutics's LinkedIn profile is https://www.linkedin.com/company/lexeo-therapeutics
Lexeo Therapeutics has
82 employees.
View email and phone details for 82
employees at Lexeo Therapeutics.
Lexeo Therapeutics's industry is
Biotechnology Research
Lexeo Therapeutics's top competitors are
Gilgamesh Pharmaceuticals,
Tourmaline Bio,
Dianthus Therapeutics, Inc.,
Anavex Life Sciences,
Royalty Pharma,
Immunic Therapeutics,
Protara Therapeutics,
Biospherix, Llc,
Nuvation Bio,
Envisagenics.
Lexeo Therapeutics's support email address is info@lexeotx.com
Lexeo Therapeutics's categories are Biotechnology Research
Lexeo Therapeutics's founding year is 2018
